Advantage Alpha Capital Partners LP Has $272,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advantage Alpha Capital Partners LP lessened its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 48.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 13,050 shares of the biopharmaceutical company’s stock after selling 12,146 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Catalyst Pharmaceuticals were worth $272,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after buying an additional 390,116 shares during the period. Pacer Advisors Inc. grew its holdings in Catalyst Pharmaceuticals by 5.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares during the period. Boston Partners raised its position in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after acquiring an additional 16,601 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after purchasing an additional 79,182 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in shares of Catalyst Pharmaceuticals by 74.3% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after purchasing an additional 312,000 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Bank of America restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $25.74 on Tuesday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16. The firm’s 50-day simple moving average is $22.46 and its 200 day simple moving average is $21.67. The stock has a market cap of $3.13 billion, a PE ratio of 21.81, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.